| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Z-Hyp-OH targets peptide synthesis and biomedical research applications as a protected hydroxyproline derivative. The Z (benzyloxycarbonyl) group protects the amino group. Hydroxyproline is an important amino acid in collagen structure and function. The compound can be used as a biomaterial for biomedical research. It does not have a specific biological receptor target.
|
|---|---|
| ln Vitro |
In vitro activity of Z-Hyp-OH is primarily as a peptide synthesis reagent and biomaterial. Amino acid derivatives have been used as ergogenic supplements, affecting the release of anabolic hormones and fuel availability. Z-Hyp-OH itself is not directly biologically active. Its utility is in preparing hydroxyproline-containing peptides for structural and biological studies.
|
| ln Vivo |
There is no specific in vivo activity data for Z-Hyp-OH as a standalone compound. Peptides containing hydroxyproline residues synthesized using this building block may be evaluated in vivo for applications related to collagen structure and function. Animal studies would be performed on the final peptide products.
|
| Enzyme Assay |
In vitro protocols for Z-Hyp-OH involve its use in peptide synthesis. The compound is activated using coupling reagents and coupled to peptides. The Z group is removed by hydrogenation or HBr in acetic acid. Purity is >98% by HPLC. Melting point is 104-107°C. Boiling point (predicted) is 486.9±45.0°C. Density is 1.416±0.06 g/cm³.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Z-Hyp-OH as it is a synthesis building block. Hydroxyproline-containing peptides synthesized using this reagent can be tested in cell culture. Peptides are dissolved in DMSO or appropriate buffers, sterile-filtered, and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability, proliferation, and collagen-related readouts.
|
| Animal Protocol |
Animal studies with Z-Hyp-OH are not conducted directly. Peptides containing hydroxyproline residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs. Hydroxyproline residues can influence collagen stability and structure.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Z-Hyp-OH as a standalone compound is not applicable. The compound has molecular weight 265.27 g/mol, formula C₁₃H₁₅NO₅, and melting point 104-107°C. Storage: room temperature. The Z group is removed by hydrogenation or acid treatment. The resulting hydroxyproline residue is important in collagen structure.
|
| Toxicity/Toxicokinetics |
Toxicological data for Z-Hyp-OH is limited. The compound is for research use only. Standard safety precautions should be observed. Acute toxicity is expected to be low. Store at room temperature. Proper personal protective equipment should be worn when handling. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Z-Hyp-OH (CAS#: 13504-85-3) is also known as trans-N-Carbobenzoxy-4-hydroxy-L-proline, trans-N-Cbz-4-hydroxy-L-proline, and (2S,4R)-4-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid. Its molecular formula is C₁₃H₁₅NO₅ and molecular weight is 265.27 g/mol. It is a protected hydroxyproline used in peptide synthesis and biomedical research. It has no approved therapeutic indications.
|
| Molecular Formula |
C13H15NO5
|
|---|---|
| Molecular Weight |
265.26
|
| Exact Mass |
265.095
|
| CAS # |
13504-85-3
|
| PubChem CID |
391517
|
| Appearance |
White to off-white powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
486.9±45.0 °C at 760 mmHg
|
| Melting Point |
104-107 °C
|
| Flash Point |
248.3±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.612
|
| LogP |
-0.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
19
|
| Complexity |
340
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=CC=C1COC(N2C(CC(C2)O)C(O)=O)=O
|
| InChi Key |
WWVCWLBEARZMAH-MNOVXSKESA-N
|
| InChi Code |
InChI=1S/C13H15NO5/c15-10-6-11(12(16)17)14(7-10)13(18)19-8-9-4-2-1-3-5-9/h1-5,10-11,15H,6-8H2,(H,16,17)/t10-,11+/m1/s1
|
| Chemical Name |
(2S,4R)-4-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
|
| Synonyms |
Z-Hyp-OH; N-Cbz-hydroxy-L-proline
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~377.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (18.85 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (18.85 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (18.85 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7699 mL | 18.8494 mL | 37.6989 mL | |
| 5 mM | 0.7540 mL | 3.7699 mL | 7.5398 mL | |
| 10 mM | 0.3770 mL | 1.8849 mL | 3.7699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
